Dare Bioscience announces effective license, collaboration pact for SST-6007.
Dare Bioscience announced that it has met the funding requirement for obtaining an exclusive worldwide license to advance SST-6007, a potential treatment for Female Sexual Arousal Disorder, or FSAD. Dare announced a license and development agreement with Strategic Science & Technologies to develop SST-6007 earlier this week. Dare plans to pursue the 505(b)(2) regulatory pathway for SST-6007 in the U.S. and leverage the existing data and established safety profile of the Viagra brand. Dare anticipates commencing a Phase 2b clinical trial in the second half of 2018 utilizing the proceeds from the investment that closed today, the company stated.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 15, 2018|
|Previous Article:||Hyatt sees FY18 adjusted EBITDA $805M-$825M.|
|Next Article:||Analysts caution against overreacting to Biogen's Alzheimer's trial change.|